Imeglimin (TWYMEEG®), an orally administered first-in-class treatment for type 2 diabetes, recently received its first approval in Japan. Population PK and PKPD models have played an important role in supporting drug development questions and the regulatory approval of imeglimin. Read more about the model-based predictions for dose adjustment in renal impaired patients here.
